G1 THERAPEUTICS (NASDAQ:GTHX) major shareholder Medimmune Ventures, Inc. sold 133,906 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $19.75, for a total value of $2,644,643.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Medimmune Ventures, Inc. also recently made the following trade(s):

  • On Monday, November 20th, Medimmune Ventures, Inc. sold 200,000 shares of G1 THERAPEUTICS stock. The stock was sold at an average price of $20.01, for a total value of $4,002,000.00.

G1 THERAPEUTICS (NASDAQ GTHX) traded down $0.62 on Tuesday, reaching $19.01. The company had a trading volume of 111,800 shares, compared to its average volume of 99,484. G1 THERAPEUTICS has a 1-year low of $12.04 and a 1-year high of $28.67.

GTHX has been the topic of a number of research reports. Cowen restated a “buy” rating on shares of G1 THERAPEUTICS in a research report on Wednesday, November 8th. Zacks Investment Research lowered G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $29.75.

Several large investors have recently made changes to their positions in GTHX. California State Teachers Retirement System bought a new stake in shares of G1 THERAPEUTICS in the third quarter worth about $319,000. Schwab Charles Investment Management Inc. purchased a new position in shares of G1 THERAPEUTICS during the third quarter valued at approximately $364,000. American International Group Inc. purchased a new position in shares of G1 THERAPEUTICS during the third quarter valued at approximately $130,000. Chartwell Investment Partners LLC increased its position in shares of G1 THERAPEUTICS by 5.0% during the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after acquiring an additional 4,388 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of G1 THERAPEUTICS during the third quarter valued at approximately $568,000. 43.25% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/05/medimmune-ventures-inc-sells-133906-shares-of-g1-therapeutics-gthx-stock.html.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.